ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q2 2019 Results - Earnings Call Transcript

ICON Public Limited Company (ICLR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: ICON Public

Icon is a top player in the CRO industry.

Icon: One Of The Best Picks Among CROs

ICON plc (ICLR) CEO Steve Cutler on Q1 2019 Results - Earnings Call Transcript

HealthEquity

ICLR vs. HQY: Which Stock Is the Better Value Option?

ICLR or HQY: Which Is the Better Value Stock Right Now?

News for ICON Stock (ICLR)